Selecting platelets for transfusion of the alloimmunized patient: a review

[1]Meryman HT.Transfusion-induced alloimmunization and immunosuppression and the effects of leukocyte depletion.Transfus Med Rev 1989;3:180.10.1016/S0887-7963(89)70078-XSearch in Google Scholar

[2]Dzik WH. Leukoreduced blood components: laboratory and clinical aspects. In Rossi EC, Simon TL, Moss GS,et al.,eds.Principles of transfusion medicine. 2nd ed. Baltimore:Williams and Wilkins, 1996: 353–73.Search in Google Scholar

[3]The Trial to Reduce Alloimmunization to Platelets (TRAP) study group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861–9.10.1056/NEJM1997122533726019417523Search in Google Scholar

[4]Sintnicolaas K, van Marwijk Kooij M,Van Prooigen HC, et al. Leukocyte depletion of random singledonor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 1995;85:824–8.10.1182/blood.V85.3.824.bloodjournal853824Search in Google Scholar

[5]Bishop JF, McGrath K,Wolf MM,et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988;71:383–7.10.1182/blood.V71.2.383.383Search in Google Scholar

[6]Friedberg RC, Donnelly SF, Boyd JC,et al. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 1993;81: 3428–34.10.1182/blood.V81.12.3428.3428Search in Google Scholar

[7]Klumpp TR,Herman J, Innis S,et al.Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation. Bone Marrow Transplant 1996;17:1035–41.Search in Google Scholar

[8]Doughty HA, Murphy MF, Metcalfe P, et al. Relative importance of immune and non-immune causes of platelet refractoriness.Vox Sang 1994;66:200–5.10.1111/j.1423-0410.1994.tb00310.x8036790Search in Google Scholar

[9]Alcorta I, Pereira A, Ordinas A. Clinical and laboratory factors associated with platelet transfusion refrac- toriness:a case-control study. Br J Haematol 1996;93: 220–4.10.1046/j.1365-2141.1996.447982.x8611465Search in Google Scholar

[10]Bock M, Muggenthaler KH, Schmidt U, et al. Influence of antibiotics on post-transfusion platelet increment.Transfusion 1996;36:952–4.10.1046/j.1537-2995.1996.36111297091736.x8937402Search in Google Scholar

[11]Dutcher JP, Schiffer CA,Aisner J,et al. Long-term follow-up of patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized. Blood 1981;58:1007–11.10.1182/blood.V58.5.1007.1007Search in Google Scholar

[12]Hogge DE, Dutcher JP, Aisner J, et al. Lympho- cytotoxic antibody is a predictor of response to random donor platelet transfusion. Am J Hematol 1983;14:363–9.10.1002/ajh.28301404076859034Search in Google Scholar

[13]Rodey GE, Neylan JF, Whelchel JD, Revels KW, BrayRA. Epitope specificity of HLA Class I allo-antibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol 1994;39:272–80.10.1016/0198-8859(94)90270-4Search in Google Scholar

[14]Duquesnoy RJ, Filip DJ, Rodey GE,et al. Successful transfusion of platelets “mismatched” for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 1977;2:219–26.10.1002/ajh.2830020303596366Search in Google Scholar

[15]MacPherson BR, Hammond PB, Maniscalco CA. Alloimmunization to public HLA antigens in multitransfused platelet recipients. Ann Clin & Lab Science 1986;16:38–44.Search in Google Scholar

[16]Lee EJ, Schiffer CA. Serial measurement of lympho- cytotoxic antibody and response to nonmatched platelet transfusion in alloimmunized patients. Blood 1987;70:1727–9.10.1182/blood.V70.6.1727.1727Search in Google Scholar

[17]Yankee RA,Grumet FC, Rogentine GN. Platelet transfusion. The selection of compatible platelet donors for refractory patients by lymphocyte HLA typing. N Engl J Med 1969;281:1208–12.10.1056/NEJM1969112728122025347838Search in Google Scholar

[18]Dahlke MB, Weiss KL. Platelet transfusion from donors mismatched for cross reactive HLA antigens. Transfusion 1984;24:299–302.10.1046/j.1537-2995.1984.24484275567.x6464151Search in Google Scholar

[19]Rachel JM,Summers TC, Sinor LT,et al. Use of a solid phase red blood cell adherence method for pretransfusion platelet compatibility testing. Am J Clin Pathol 1988;90:63–8.10.1093/ajcp/90.1.633389344Search in Google Scholar

[20]Gelb AB, Leavitt AD. Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets. Transfusion 1997;37:624–30.10.1046/j.1537-2995.1997.37697335157.x9191823Search in Google Scholar

[21]Petz LD,Garratty G, Clark BD,et al.The effectiveness of an antibody specificity prediction (ASP) method for selecting platelets for transfusion to alloimmunized patients (abstract). Blood 1995;86:546a.Search in Google Scholar